Friday, 16 October 2026European Markets

BOIRON Stock Bullish Momentum With A 28% Rise In The Last 21 Sessions

Loading stream...

french pharmaceutical company boiron, listed on cac 40 as boi.pa, made headlines recently when its shares surged 28.57% over 21 sessions. despite three successive losses, the company's shares climbed from eur39.2 to eur50.40. albeit the closing value was eur50.30, 5.45% below boiron's 52-week high of eur53.20, the significant rise was noteworthy in the market.

overview of boiron

boiron is a well-established pharmaceutical company founded in 1932. the company specializes in the production of homeopathic medicines, healthcare items - encompassing dietary supplements and cosmetics - and homecare solutions. boiron addresses the medical needs of various regions across france, europe, north america, and other international markets. as a result, it possesses an impressive presence worldwide, with its product portfolio catering to a diverse array of medical demands.

financial performance of boiron

over the past 12 months, boiron recorded an earnings per share (eps) of eur 2.89. the company currently exhibits a price-to-earnings (pe) ratio of 17.44, implying that investors are paying eur17.44 for every euro of annual earnings reported by the company. furthermore, boiron demonstrated a commendable return on equity (roe), a measure of a company's profitability against shareholders' equity, at 8.13% for its latest operational year. it's notable to investors seeking regular income that the next dividend payment is due for june 1st with an anticipated forward annual dividend yield of 2.19%.

market fluctuations and boiron stocks

boiron stocks have seen significant market fluctuations of late, with a weekly, monthly, and quarterly intraday average variation wavering between -0.07%, +1.82% and +1.35%, respectively. despite these fluctuations and below-average trading volumes, boiron's stock value has remained strong. on monday's trading, boiron settled at a price of eur50.40, considerably above its 52-week low of eur37.00.

concluding thoughts

the highly volatile nature of the stock market can be challenging for investors. however, boiron's recent performance underscores the importance of resilience and the efficacy of long-term strategies triumphing over short-term losses. boiron, through its robust performance amidst market fluctuations, serves as an encouraging example in the investing world.

more news about boiron (boi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com